Recruiting

A Study to Find and Confirm Blood-based Markers (Called Proteins) That May Show Early Heart Changes in Women With Preeclampsia, Even Before Symptoms Appear, and the Use of Heart Ultrasound (Echocardiography) to Look at Patterns of How the Heart Changes During Pregnancy in Women With Preeclampsia

The goal of this study is to find and confirm blood-based markers (called proteins) that may show early heart changes in women with preeclampsia, even before symptoms appear. It will also use heart ultrasound (echocardiography) to look at patterns of how the heart changes during pregnancy in women with preeclampsia. The main questions it aims to answer are: * Do these blood markers relate to heart changes on ultrasound? * How may they help predict future health problems for the mother? Participants will: *…

ClinicalTrials.gov IDNCT07463898
PhaseNot Applicable
Enrollment172
SponsorWashington University School of Medicine
Age13 Years
SexFEMALE
I'm interested View official listing

Conditions studied

Cardiovascular Biomarkers, Preeclampsia (PE) Risk, Preeclampsia (PE)

About this study

The goal of this study is to find and confirm blood-based markers (called proteins) that may show early heart changes in women with preeclampsia, even before symptoms appear. It will also use heart ultrasound (echocardiography) to look at patterns of how the heart changes during pregnancy in women with preeclampsia. The main questions it aims to answer are: * Do these blood markers relate to heart changes on ultrasound? * How may they help predict future health problems for the mother? Participants will: * Complete a 20-minute survey that will include taking your baseline demographic information, clinical information/medical history, asking about pre-existing health conditions, including measuring your height, weight, and blood pressure. * Have transthoracic echocardiography (TTE) performed at 12 - 16 weeks gestation and again at 28 - 32 weeks gestation. * Provide a blood sample for these protein measurements. These samples will be collected at intake (12 - 16 weeks gestation) and again at 28 - 32 weeks gestation.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * • Pregnant women who are up to 20 weeks pregnant * Able to consent to participate in the study * Are enrolled in the ENHANCE-CVH study * Willing to undergo echocardiography and blood draws Exclusion Criteria: * • Known cardiac disease (e.g., cardiomyopathy, coronary artery disease \[CAD\]) * Sickle cell disease * Pulmonary arterial hypertension * Pulmonary embolism * Inability to provide informed consent * Acute Illness * Malignancy

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.